Lobbyists get $47.4M windfall from pharma

We thought Big Pharma was lobbying hard ahead of last year's presidential election. Drugmakers spent millions on their lobbyists, even as they ploughed millions into the campaigns, for the first time splitting their votes fairly evenly between Democrats and Republicans. But even so, pharma's spending on lobbying leapt during the first quarter by 36 percent, to $47.4 million.

You can bet the lobbyists are grateful. According to the Wall Street Journal, pharma is one of the few industries to boost lobbying expenses during this economic downturn. Overall lobbying is relatively flat year-over-year, so drugmakers are handing out a bigger piece of the spending pie. Of course pharma has plenty at stake these days. With the Obama administration intent on reforming healthcare and trimming spending on it, drugmakers stand to lose plenty.

Among the biggest pharma lobbyists: Pfizer, with $6.1 million plunked down during the first quarter, up from $2.8 million the same quarter last year. Then there's PhRMA, the trade association, which spent $6.9 million, almost double the $3.6 million it spent last year. Bayer, GlaxoSmithKline and Merck each boosted their lobbying spending by at least 40 percent year-over-year.

- read the WSJ report

Suggested Articles

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.